OBJECTIVE: Atypical neuroleptics, including @entity1090 , are used to treat @entity1 with @entity2438 , despite limited efficacy and safety data. Many clinicians believe that @entity1090 will not induce @entity910 in @entity1 . The authors investigated open @entity1090 treatment in @entity1 with @entity2438 and included findings on @entity910 . METHOD: The sample included 22 outpatients (mean age = 7.1 years) diagnosed with @entity2438 (DSM-IV). Treatment consisted of a 1-month short-term phase followed by a 6-month long-term phase. At the end of the long-term phase, drug was discontinued, and the need for further drug treatment and the occurrence of @entity910 were assessed. Measures included the Clinical Global Impressions (CGI), @entity1 's Psychiatric Rating Scale (CPRS), and the @entity910 Scale. RESULTS: The mean @entity1090 dosage was 1.2 mg/day. Overall, the @entity1 had significant clinical improvement as assessed by the CPRS and CGI. Untoward effects included sedation, increased appetite, and @entity1017 . Two of 13 (15.4%) @entity1 treated long-term developed mild, reversible @entity910 when @entity1090 was discontinued. No @entity1 developed @entity910 on @entity1090 . CONCLUSIONS: @entity1090 shows promise as a treatment in @entity2438 . However, @entity910 were noted. Further assessment of the risk of @entity1090 -related @entity910 is indicated.

@entity1090 treatment in XXXX and adolescents with @entity2438 : short- and long-term safety and effectiveness.

@entity1 :: ('9606', 'Species') :: ['children', 'Children', 'child'] @entity2438 :: ('MESH:D001321', 'Disease') :: ['autism'] @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesias', 'Abnormal Involuntary Movement', 'withdrawal dyskinesias'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone', 'Risperidone']
@entity1 :: (9606,Species) :: ['children']
